No Data
No Data
Kai Kai Industrial (600272.SH): Net profit of 23.26 million yuan in the first quarter increased by 137.46% year-on-year
On April 26, Ge Longhui Industrial (600272.SH) released its first quarter report. Operating revenue was 234 million yuan, up 17.42% year on year, net profit of 23.26 million yuan, up 137.46% year on year, after deducting non-net profit of 230,000 yuan, down 92.73% year on year, with basic earnings of 0.096 yuan per share.
Express News | The SPD concept was partially strengthened. First Pharmaceuticals boosted the touchpad, and Medicinal Ecommerce, Heavy Pharmaceutical Holdings, and the opening of the industrial sector followed suit.
Pharmaceutical commercial stocks fluctuated higher, and First Pharmaceutical hit a rise or fall in the afternoon. E-Commerce, Heavy Pharmaceutical Holdings, Kaikai Industrial, Dashenlin, and Yifeng Pharmacy had the highest gains.
Pharmaceutical commercial stocks fluctuated higher, and First Pharmaceutical hit a rise or fall in the afternoon. E-Commerce, Heavy Pharmaceutical Holdings, Kaikai Industrial, Dashenlin, and Yifeng Pharmacy had the highest gains.
Kaikai Industrial (600272.SH): Net profit in 2023 fell 1.57% year on year, and plans to pay 10 0.49 yuan
On March 29, Ge Longhui Industrial (600272.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 925 million yuan, an increase of 3.46%; net profit attributable to shareholders of listed companies of 393.01 million yuan, a year-on-year decrease of 1.57%; net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses of 9.4456 million yuan, a year-on-year decrease of 33.21%; and basic earnings per share of 0.16 yuan. The company's 2023 profit distribution plan: The company plans to distribute profits based on the total share capital registered on the equity registration date, to all shareholders for every 1
Start a business (600272.SH): No related business such as drug R&D or production
On February 23, Gelonghui Industrial (600272.SH) said on an interactive platform that the company has no related business such as drug R&D or production. The company's main business is the distribution of traditional Chinese medicine, traditional Chinese medicine services (traditional Chinese medicine consultation service), and wholesale and retail of clothing. Various retail stores under the company's pharmaceutical division sell related weight loss drugs. It is recommended that you follow the doctor's instructions carefully when purchasing according to your own circumstances.
The A-share pharmaceutical commercial sector fluctuated and rose, and Hefu China directly rose and stopped
Gelonghui, Feb. 20 | Hefu China went up and down in a straight line, opening up more than 8%, while Guoke Hengtai, Saili Healthcare, Dajia Weikang, and Chinese Health followed suit.
No Data